The multicenter, prospective Stimulation Therapy for Apnea Reduction (STAR) trial was conducted at 22 medical centers in the United States and Europe, and is the first to evaluate the use of upper airway stimulation for sleep apnea.
This image shows how the Inspire® Upper Airway Stimulation Therapy device works.
OSA, which affects more than 8 million men and 4 million women in the U.S. and is twice as common in men, is characterized by repeated episodes of upper airway collapse during sleep, due to narrowing or blockage.
Patients with OSA stop breathing, known as apnea, frequently during sleep, often for a minute or longer, and over half of those with OSA are overweight. Repeated episodes of apnea can lead to daytime fatigue, and increase a person's risk for heart attack, stroke, high blood pressure and even death.
Treatments for OSA include weight loss, upper airway surgeries, oral appliances, and continuous positive airway pressure (CPAP), which is considered the primary treatment for OSA.
"While CPAP is a successful treatment when used on a regular basis, as many as half of the patients who have been prescribed CPAP are unable to use it regularly, largely due to discomfort with the mask and/or the lack of desire to be tethered to a machine," said Patrick Strollo, M.D., professor of medicine and clinical and translational science at the University of Pittsburgh School of Medicine, medical director of the UPMC Sleep Medicine Center, and lead author of the study. "The results of this trial show a huge potential for a new and effective treatment that can help millions of patients."
"Inspire UAS therapy differs from other traditional sleep apnea devices and surgical procedures in that it targets the muscle tone of the throat rather than just the anatomy," noted Ryan Soose, M.D., director of the UPMC Division of Sleep Surgery and assistant professor at the University of Pittsburgh School of Medicine, Department of Otolaryngology. "Two thirds of patients using the Inspire UAS therapy device had successful control of their OSA although even more reported improvement in snoring, daytime sleepiness and quality of life measures. Eighty-six percent of patients were still using the device every night at the one year mark, which compares very favorably to CPAP."
From 724 candidates initially screened, the STAR trial implanted and prospectively evaluated 126 moderate-to-severe OSA patients who had difficulty using or adhering to CPAP therapy:
•83 percent of the participants were men, the mean age was 54.5 years, and the mean body-mass index was 28.4.
•All patients underwent surgery to implant the device. The device stimulates the nerve of the tongue during sleep, thereby enlarging and stabilizing the airway and improving control of breathing.
•Surgical implantation of the upper-airway stimulation system was performed by otolaryngologists at 22 academic and private centers, including Ryan Soose, M.D., of UPMC Ear, Nose and Throat specialists.
•The device was implanted in three areas: a stimulation electrode was placed on the hypoglossal nerve, which provides innervation to the muscles of the tongue; a sensing lead was placed between rib muscles to detect breathing effort; and a neurostimulator was implanted in the upper right chest, just below the clavicle bone.
•Patients used a "controller" to turn on the device at night, so it is only used when the patient sleeps. The Inspire UAS therapy device is designed to sense breathing patterns and deliver mild stimulation to a patient's airway muscles to keep the airway open during sleep.
•Using various sleep-disorder measuring systems, patients were found to experience 68 to 70 percent fewer sleep-apnea episodes per hour.
"My short-term memory has improved significantly, and the surgery has made a huge difference in my quality of life," said Kathy Gaberson, one of the study participants who used the Inspire therapy. "My apnea episodes went from 23 times an hour to just two."
This study was funded by Inspire Medical Systems.
Dr. Soose is a consultant for Inspire Medical Systems.
Co-investigators include researchers from University Hospital, Mannheim; Intersom K.ln, Cologne; Sint Lucas Hospital, Amsterdam; North Memorial Sleep Health Center, Maple Grove; Paparella Ear, Head, and Neck Institute; St. Cloud Ear, Nose, and Throat; the University of South Florida College of Medicine; the St. Petersburg Sleep Disorders Center; the University of Cincinnati; the Medical College of South Carolina, Charleston; the Medical College of Wisconsin; Antwerp University Hospital; the University of Antwerp; the Borgess Medical Center; the Louis Stokes Cleveland Veterans Affairs Medical Center; and, Case Western Reserve University.About the University of Pittsburgh Schools of the Health Sciences
http://www.upmc.com/mediaContact: Cristina Mestre
Cristina Mestre | EurekAlert!
A non-invasive tool for diagnosing cancer*
21.05.2015 | The Agency for Science, Technology and Research (A*STAR)
PolyU develops novel computer intelligence system for acute stroke detection
20.05.2015 | The Hong Kong Polytechnic University
Physicists have developed an innovative method that could enable the efficient use of nanocomponents in electronic circuits. To achieve this, they have developed a layout in which a nanocomponent is connected to two electrical conductors, which uncouple the electrical signal in a highly efficient manner. The scientists at the Department of Physics and the Swiss Nanoscience Institute at the University of Basel have published their results in the scientific journal “Nature Communications” together with their colleagues from ETH Zurich.
Electronic components are becoming smaller and smaller. Components measuring just a few nanometers – the size of around ten atoms – are already being produced...
Development and implementation of an advanced automobile parking navigation platform for parking services
To fulfill the requirements of the industry, PolyU researchers developed the Advanced Automobile Parking Navigation Platform, which includes smart devices,...
The world's first electrical car and passenger ferry powered by batteries has entered service in Norway. The ferry only uses 150 kWh per route, which...
On Tuesday, 19 May 2015 the research icebreaker Polarstern will leave its home port in Bremerhaven, setting a course for the Arctic. Led by Dr Ilka Peeken from the Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research (AWI) a team of 53 researchers from 11 countries will investigate the effects of climate change in the Arctic, from the surface ice floes down to the seafloor.
RV Polarstern will enter the sea-ice zone north of Spitsbergen. Covering two shallow regions on their way to deeper waters, the scientists on board will focus...
Nanoengineers at the University of California, San Diego developed a gel filled with toxin-absorbing nanosponges that could lead to an effective treatment for skin and wound infections caused by MRSA (methicillin-resistant Staphylococcus aureus), an antibiotic-resistant bacteria. This "nanosponge-hydrogel" minimized the growth of skin lesions on mice infected with MRSA - without the use of antibiotics. The researchers recently published their findings online in Advanced Materials.
To make the nanosponge-hydrogel, the team mixed nanosponges, which are nanoparticles that absorb dangerous toxins produced by MRSA, E. coli and other...
20.05.2015 | Event News
18.05.2015 | Event News
12.05.2015 | Event News
22.05.2015 | Materials Sciences
22.05.2015 | Information Technology
22.05.2015 | Materials Sciences